Precision medicine in epilepsy: Clinicians' perspectives from an international qualitative study
Clinicians consider PM as transformative for the care for PWE and expect it to redefine standard practice in the near future. Insufficient knowledge is the primary barrier to PM implementation, irrespective of socioeconomic context, highlighting the need for its integration into basic medical training and residency programs. To address inequities, integrated care pathways and standardized guidelines for genetic testing and PM, and the establishment of local PM-focused expert teams are essential to support clinicians in making informed PM decisions.
Authors
- Sarah Weckhuysen (ORCID: https://orcid.org/0000-0003-2878-1147)
- Anna Jansen (ORCID: https://orcid.org/0000-0002-3835-2824)
- Berten Ceulemans (ORCID: https://orcid.org/0000-0001-7818-0679)
- Annelies Colliers (ORCID: https://orcid.org/0000-0003-4960-2355)
- Matthias De Wachter (ORCID: https://orcid.org/0000-0002-6422-210X)
- Rikke S. Møller (ORCID: https://orcid.org/0000-0002-9664-1448)
- Anne Juul
Institutions
- University of Antwerp (BE)
- University of Southern Denmark (DK)
- Vlaams Instituut voor Biotechnologie (BE)
- Antwerp University Hospital (BE)
- VIB-UAntwerp Center for Molecular Neurology (BE)
- Epilepsy Action (GB)
- Epilepsy Foundation (AU)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1111/epi.18480
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fonds Wetenschappelijk Onderzoek
- European Academy of Neurology
- Universitair Ziekenhuis Antwerpen